Top Seattle, WA Biotech Companies (43)
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for pro-innovation/pro-patient policies.
ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory. Over the last two decades, our founder and Executive Chairman Dr. Patrick Soon-Shiong has investigated mechanisms to activate the immune system to attack tumors that can otherwise evade and escape the body’s defense mechanisms. After inventing the world’s first protein nanoparticle drug, Abraxane, Dr. Soon-Shiong turned his focus to the next generation of immunotherapies. ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious diseases. "At ImmunityBio, we envision a day when we no longer fear cancer but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease." -Dr. Patrick Soon-Shiong, Executive Chairman
Lightspeed Microscopy Inc. reimagines pathology by providing a full-stack solution to nondestructively image large tissues in 3D at sub-cellular resolution. Its novel chemistry, patented high-throughput light-sheet microscope, and cloud-based AI analysis software adds a new dimension to pathology. Lightspeed, spun-out of the University of Washington and co-founded by Nick Reder in 2018, is based in Seattle, WA.
"Human Data for Next Generation Medicines" Curi Bio unlocks novel workflows and critical human data to inform R&D decision-making. Through an integrated platform featuring advanced 3D tissue models of disease, biosystems enabling clinically relevant functional analyses, and AI/ML-enabled insights, Curi Bio merges functional and analytical assessments for drug safety, efficacy, and potency.
Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics.
The vast majority of human disease is governed by the epigenome, the subtle machinery that controls the volume of gene expression in cells. Tune Therapeutics is pioneering the creation of epi-therapeutic medicines with its powerful and precise epigenomic control platform, TEMPO. Unlike genome editing, TEMPO dials the volume of gene expression up or down towards healthy levels, without breaking or permanently rewriting DNA – and it can do this in multiple genes at once. This genetic tuning approach allows us to change cell fate and function at will, unlocking the ability to reverse pathways of cancer, genetic disease and aging. Our approach effectively expands the potential reach of genetic medicine – from targeting a limited range of rare conditions, to overcoming thousands of complex and chronic diseases that currently have no curative treatment.
At A-Alpha Bio, we aim to accelerate target discovery, library screening, and preclinical drug characterization by providing cell-based tools for quantitative and high-throughput measurements of protein interactions. Current approaches for measuring protein interactions are insufficient for many drug development applications due to low accuracy or throughput. We are a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck. AlphaSeq is a revolutionary cell-based platform technology that will fundamentally change the way that protein interactions are measured. We are seeking industry partnerships to evaluate the use of AlphaSeq for a variety of drug development applications. A-Alpha Bio, Inc. was founded in 2017 as a spinout from the University of Washington's Institute for Protein Design and Center for Synthetic Biology.
Kineta is a privately held emerging biotech company that was founded in 2008. Our mission is to develop novel immunotherapies that transform patients’ lives.
We are designing RNA for next generation biomanufacturing and smart therapeutics. https://wayfinderbio.com
SEngine Precision Medicine brings the latest advances in cancer research and treatment to the fight against cancer. With a focus on functional screening, genomics, robotics, cancer organoid cultures, and bioinformatics, SEngine Precision Medicine is providing invaluable data to oncologists and realizing the promise of precise, less toxic and more effective therapies to cancer patients. The accumulation of data is essential to pharmaceutical companies to accelerate the success of cancer treatments. SEngine is CLIA certified to receive your sample today.
Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems. Adaptive’s proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are applying these insights to develop products that will transform the way diseases -- such as cancer, autoimmune conditions, and infectious diseases -- are diagnosed and treated. For more information, please visit adaptivebiotech.com.
ShapeTX is pioneering the field of programmable RNA medicines to repair the genetic causes of diseases. By merging innovations in AI and RNA technology to generate and analyze hundreds of billions of therapeutic possibilities, ShapeTX is developing breakthroughs in RNA editing, next-generation AAVs, and disruptive gene therapy manufacturing. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer’s, Parkinson’s, and many more.
Just – Evotec Biologics is an integrated design company focused on technologies that will accelerate development of biotherapeutics and substantially reduce their manufacturing cost.
AltPep develops early disease-modifying treatments and detection tools for amyloid diseases by targeting one of the earliest molecular triggers – toxic soluble oligomers. These oligomers are associated with many diseases, including neurodegenerative diseases and type 2 diabetes. Decades of scientific research by the Daggett Research Group culminated in the discovery of a novel protein structure, alpha-sheet, the foundation of our innovative approach. Our lead program aims to identify Alzheimer’s Disease long before symptoms occur and then neutralize the toxic soluble oligomers associated with the disease.
Enabling the next generation of breakthroughs in treating human disease.
Viome is on a mission to prevent and reverse chronic diseases. Viome is a high-growth biotech startup that applies AI and machine learning to biological data – e.g., microbiome, transcriptome and metabolome data – to provide direct-to-consumer personalized dietary and lifestyle recommendations for healthier living. We are a small, fast-growing, interdisciplinary team of passionate experts in biochemistry, microbiology, medicine, artificial intelligence, and machine learning with a shared mission to make illness optional.
PreemptiveAI is building the foundation model that maps human physiology/pathology and predicts health outcomes in real-time via biomedical signals from smartphones and wearable devices.
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com. Together with our customers, we are driven to make healthcare better.
Tasso is a fast-growing Seattle-based startup focused on delivering at-home diagnostic testing to those who need it most. We are growing our footprint with leading health systems, clinical research organizations, academic medical centers, and more who are looking to deliver clinical-grade, convenient diagnostic tests to their patients. Tasso was originally founded to find a better way to collect blood instead of a painful fingerstick or time-consuming venous draw. Since then, our products have been used in pharmaceutical clinical trials, by Olympians as part of a new virtual anti-doping program, and broadly by hospital systems across the US.
Oscine Therapeutics is a new biotechnology company based on discoveries made and developed at the University of Rochester Medical Center
Work Your Passion. Live Your Purpose.
Industry
Work Your Passion. Live Your Purpose.
